AUPO390396A0 - Novel promiscuous T helper cell epitopes - Google Patents

Novel promiscuous T helper cell epitopes

Info

Publication number
AUPO390396A0
AUPO390396A0 AUPO3903A AUPO390396A AUPO390396A0 AU PO390396 A0 AUPO390396 A0 AU PO390396A0 AU PO3903 A AUPO3903 A AU PO3903A AU PO390396 A AUPO390396 A AU PO390396A AU PO390396 A0 AUPO390396 A0 AU PO390396A0
Authority
AU
Australia
Prior art keywords
cell epitopes
helper cell
promiscuous
novel
novel promiscuous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPO3903A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
CSL Ltd
Original Assignee
University of Queensland UQ
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, CSL Ltd filed Critical University of Queensland UQ
Priority to AUPO3903A priority Critical patent/AUPO390396A0/en
Publication of AUPO390396A0 publication Critical patent/AUPO390396A0/en
Priority to AU51112/98A priority patent/AU5111298A/en
Priority to PCT/AU1997/000820 priority patent/WO1998023635A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AUPO3903A 1996-11-29 1996-11-29 Novel promiscuous T helper cell epitopes Abandoned AUPO390396A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AUPO3903A AUPO390396A0 (en) 1996-11-29 1996-11-29 Novel promiscuous T helper cell epitopes
AU51112/98A AU5111298A (en) 1996-11-29 1997-12-01 Novel promiscuous t helper cell epitopes
PCT/AU1997/000820 WO1998023635A1 (en) 1996-11-29 1997-12-01 Novel promiscuous t helper cell epitopes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO3903A AUPO390396A0 (en) 1996-11-29 1996-11-29 Novel promiscuous T helper cell epitopes

Publications (1)

Publication Number Publication Date
AUPO390396A0 true AUPO390396A0 (en) 1996-12-19

Family

ID=3798212

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPO3903A Abandoned AUPO390396A0 (en) 1996-11-29 1996-11-29 Novel promiscuous T helper cell epitopes

Country Status (2)

Country Link
AU (1) AUPO390396A0 (en)
WO (1) WO1998023635A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK4272001A3 (en) 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
ID28387A (en) * 1998-10-05 2001-05-17 M & E Biotech As A NEW METHOD FOR THERAPEUTIC VACCINATION
HUP0200958A3 (en) 1999-04-23 2004-11-29 Pharmexa As Method for down-regulating il5 activity
FR2794370B1 (en) * 1999-06-03 2003-10-17 Biovector Therapeutics POLYEPITOPIC PROTEIN FRAGMENTS, THEIR OBTAINMENT AND THEIR USES IN PARTICULAR IN VACCINATION
TR200400621T2 (en) 1999-07-20 2004-08-23 Pharmexa A/S A method for downregulating GDF-8 activity.
FR2794371B1 (en) * 1999-10-07 2004-06-18 Biovector Therapeutics POLYEPITOPIC PROTEIN FRAGMENTS, THEIR OBTAINMENT AND THEIR USES IN PARTICULAR IN VACCINATION
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
EP1237930B1 (en) * 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Chimeric amyloid beta peptides
AU783144B2 (en) 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
EP1947174A1 (en) * 2000-06-21 2008-07-23 MedImmune, LLC Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
NZ567324A (en) 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
EA013752B1 (en) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Prevention and treatment of synucleinopathic and amyloidogenic disease
DK1810026T3 (en) 2004-10-06 2018-07-16 Mayo Found Medical Education & Res B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
JP2008044848A (en) * 2004-11-30 2008-02-28 Univ Kurume HLA-A24 restricted tumor antigen peptide
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
DK2596801T3 (en) 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
EP2124998B8 (en) 2006-12-27 2015-05-06 The Johns Hopkins University Methods for detecting inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
HUE043966T2 (en) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2583978T3 (en) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080292625A1 (en) 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
EP2908851A1 (en) 2012-10-19 2015-08-26 Bavarian Nordic Inc. Methods and compositions for the treatment of cancer
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
ES2714708T3 (en) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedures for the treatment of cancer in patients with elevated levels of Bim
JP2017501848A (en) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド Monitoring immunotherapy of Lewy body disease from constipation symptoms
ES2851451T3 (en) 2014-05-13 2021-09-07 Bavarian Nordic As Combination therapy to treat cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
MX2018013386A (en) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Antibodies recognizing tau.
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
KR102784294B1 (en) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 Tau recognition antibody
CA3066026A1 (en) 2017-06-14 2018-12-20 Virometix Ag Cyclic peptides for protection against respiratory syncytial virus
JP7555334B2 (en) 2018-10-05 2024-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ Combination therapy to treat cancer by intravenous administration of recombinant MVA and immune checkpoint antagonist or immune checkpoint agonist
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
CA3119503A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
JP7550762B2 (en) 2018-12-20 2024-09-13 ヴァイロメティックス アーゲー Lipopeptide Building Blocks and Synthetic Virus-Like Particles
JP7630834B2 (en) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド Tau recognition antibody
US20230190922A1 (en) 2019-11-20 2023-06-22 Bavarian Nordic A/S Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
BR112022026508A2 (en) 2020-06-24 2023-03-07 Prothena Biosciences Ltd ANTIBODIES THAT RECOGNIZE SORTILIN
WO2021260176A1 (en) 2020-06-25 2021-12-30 Virometix Ag Synthetic epitopes of betacoronaviruses
EP4216992A1 (en) 2020-09-28 2023-08-02 DBV Technologies Particle comprising an rsv-f protein for use in rsv vaccination
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CN121693342A (en) 2023-07-12 2026-03-17 维罗迈科斯股份公司 Composition of pneumococcal antigen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001705D0 (en) * 1990-05-11 1990-05-11 Medscand Ab SET FOR DIAGNOSTICS OF VIRUS BREAKING TUMORS BY IMMUNOASSAY

Also Published As

Publication number Publication date
WO1998023635A1 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
AUPO390396A0 (en) Novel promiscuous T helper cell epitopes
AU6679598A (en) Chair pack
AU4327197A (en) Chuck
AU1795197A (en) Radiotelephone
AU3739897A (en) Rechargeable positive electrodes
AU5001097A (en) Modular radiotelephone
AU7892694A (en) Battery separator
AU1251797A (en) Novel heteroaryl-oxazolidinones
AU8777898A (en) Methods for genetically modifying t cells
AUPO129496A0 (en) Photoelectrochemical cell
AU5185799A (en) Pack
AU6936198A (en) Separator
AU8243798A (en) Agm-derived stroma cells
AU7582598A (en) Chuck
AU3026497A (en) Benzothiazolinones as anti-asthmatic agents
AU3913895A (en) Sterilization cell
AU3545197A (en) Bioclimatological station
AU2104497A (en) Cell stimulation
AU5111298A (en) Novel promiscuous t helper cell epitopes
AU1913099A (en) Battery separator
AU3873697A (en) Novel aryl-pyridazines
AU3276697A (en) Cell compositions
AU3400795A (en) Separator
AUPM473994A0 (en) Separator
AU3638097A (en) Inverted loudspeakers